Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy
Cardiac resynchronization therapy represents a therapeutic option for heart failure drug-refractory patients. However, due to the lack of success in 30% of the cases, there is a demand for an in-depth analysis of individual heterogeneity. In this study, we aimed to evaluate the prognostic value of c...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-01-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/2/271 |
| _version_ | 1797495155622674432 |
|---|---|
| author | Isabel Moscoso María Cebro-Márquez Álvaro Martínez-Gómez Charigan Abou-Jokh María Amparo Martínez-Monzonís José Luis Martínez-Sande Laila González-Melchor Javier García-Seara Xesús Alberte Fernández-López Sandra Moraña-Fernández José R. González-Juanatey Moisés Rodríguez-Mañero Ricardo Lage |
| author_facet | Isabel Moscoso María Cebro-Márquez Álvaro Martínez-Gómez Charigan Abou-Jokh María Amparo Martínez-Monzonís José Luis Martínez-Sande Laila González-Melchor Javier García-Seara Xesús Alberte Fernández-López Sandra Moraña-Fernández José R. González-Juanatey Moisés Rodríguez-Mañero Ricardo Lage |
| author_sort | Isabel Moscoso |
| collection | DOAJ |
| description | Cardiac resynchronization therapy represents a therapeutic option for heart failure drug-refractory patients. However, due to the lack of success in 30% of the cases, there is a demand for an in-depth analysis of individual heterogeneity. In this study, we aimed to evaluate the prognostic value of circulating miRNA differences. Responder patients were defined by a composite endpoint of the presence of left ventricular reverse remodelling (a reduction ≥15% in telesystolic volume and an increment ≥10% in left ventricular ejection fraction). Circulating miRNAs signature was analysed at the time of the procedure and at a 6-month follow-up. An expression analysis showed, both at baseline and at follow-up, differences between responders and non-responders. Responders presented lower baseline expressions of miR-499, and at follow-up, downregulation of miR-125b-5p, both associated with a significant improvement in left ventricular ejection fraction. The miRNA profile differences showed a marked sensitivity to distinguish between responders and non-responders. Our data suggest that miRNA differences might contribute to prognostic stratification of patients undergoing cardiac resynchronization therapy and suggest that preimplant cardiac context as well as remodelling response are key to therapeutic success. |
| first_indexed | 2024-03-10T01:44:24Z |
| format | Article |
| id | doaj.art-994b98cd31ef450898163822bb2be33e |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-10T01:44:24Z |
| publishDate | 2022-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-994b98cd31ef450898163822bb2be33e2023-11-23T13:18:49ZengMDPI AGCells2073-44092022-01-0111227110.3390/cells11020271Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization TherapyIsabel Moscoso0María Cebro-Márquez1Álvaro Martínez-Gómez2Charigan Abou-Jokh3María Amparo Martínez-Monzonís4José Luis Martínez-Sande5Laila González-Melchor6Javier García-Seara7Xesús Alberte Fernández-López8Sandra Moraña-Fernández9José R. González-Juanatey10Moisés Rodríguez-Mañero11Ricardo Lage12Cardiology Group, Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, SpainCardiology Group, Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, SpainDepartment of Cardiology and Coronary Unit and Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS-SERGAS), University Clinical Hospital, 15706 Santiago de Compostela, SpainDepartment of Cardiology and Coronary Unit and Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS-SERGAS), University Clinical Hospital, 15706 Santiago de Compostela, SpainDepartment of Cardiology and Coronary Unit and Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS-SERGAS), University Clinical Hospital, 15706 Santiago de Compostela, SpainDepartment of Cardiology and Coronary Unit and Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS-SERGAS), University Clinical Hospital, 15706 Santiago de Compostela, SpainDepartment of Cardiology and Coronary Unit and Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS-SERGAS), University Clinical Hospital, 15706 Santiago de Compostela, SpainDepartment of Cardiology and Coronary Unit and Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS-SERGAS), University Clinical Hospital, 15706 Santiago de Compostela, SpainDepartment of Cardiology and Coronary Unit and Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS-SERGAS), University Clinical Hospital, 15706 Santiago de Compostela, SpainDepartment of Cardiology and Coronary Unit and Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS-SERGAS), University Clinical Hospital, 15706 Santiago de Compostela, SpainCardiology Group, Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, SpainDepartment of Cardiology and Coronary Unit and Cellular and Molecular Cardiology Research Unit, Institute of Biomedical Research (IDIS-SERGAS), University Clinical Hospital, 15706 Santiago de Compostela, SpainCardiology Group, Centre for Research in Molecular Medicine and Chronic Diseases (CIMUS), Universidade de Santiago de Compostela, 15782 Santiago de Compostela, SpainCardiac resynchronization therapy represents a therapeutic option for heart failure drug-refractory patients. However, due to the lack of success in 30% of the cases, there is a demand for an in-depth analysis of individual heterogeneity. In this study, we aimed to evaluate the prognostic value of circulating miRNA differences. Responder patients were defined by a composite endpoint of the presence of left ventricular reverse remodelling (a reduction ≥15% in telesystolic volume and an increment ≥10% in left ventricular ejection fraction). Circulating miRNAs signature was analysed at the time of the procedure and at a 6-month follow-up. An expression analysis showed, both at baseline and at follow-up, differences between responders and non-responders. Responders presented lower baseline expressions of miR-499, and at follow-up, downregulation of miR-125b-5p, both associated with a significant improvement in left ventricular ejection fraction. The miRNA profile differences showed a marked sensitivity to distinguish between responders and non-responders. Our data suggest that miRNA differences might contribute to prognostic stratification of patients undergoing cardiac resynchronization therapy and suggest that preimplant cardiac context as well as remodelling response are key to therapeutic success.https://www.mdpi.com/2073-4409/11/2/271heart failureadverse remodellingcardiac resynchronization therapymicroRNAscardiac biomarkercardiac therapeutic target |
| spellingShingle | Isabel Moscoso María Cebro-Márquez Álvaro Martínez-Gómez Charigan Abou-Jokh María Amparo Martínez-Monzonís José Luis Martínez-Sande Laila González-Melchor Javier García-Seara Xesús Alberte Fernández-López Sandra Moraña-Fernández José R. González-Juanatey Moisés Rodríguez-Mañero Ricardo Lage Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy Cells heart failure adverse remodelling cardiac resynchronization therapy microRNAs cardiac biomarker cardiac therapeutic target |
| title | Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy |
| title_full | Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy |
| title_fullStr | Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy |
| title_full_unstemmed | Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy |
| title_short | Circulating miR-499a and miR-125b as Potential Predictors of Left Ventricular Ejection Fraction Improvement after Cardiac Resynchronization Therapy |
| title_sort | circulating mir 499a and mir 125b as potential predictors of left ventricular ejection fraction improvement after cardiac resynchronization therapy |
| topic | heart failure adverse remodelling cardiac resynchronization therapy microRNAs cardiac biomarker cardiac therapeutic target |
| url | https://www.mdpi.com/2073-4409/11/2/271 |
| work_keys_str_mv | AT isabelmoscoso circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT mariacebromarquez circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT alvaromartinezgomez circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT chariganaboujokh circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT mariaamparomartinezmonzonis circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT joseluismartinezsande circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT lailagonzalezmelchor circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT javiergarciaseara circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT xesusalbertefernandezlopez circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT sandramoranafernandez circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT josergonzalezjuanatey circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT moisesrodriguezmanero circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy AT ricardolage circulatingmir499aandmir125baspotentialpredictorsofleftventricularejectionfractionimprovementaftercardiacresynchronizationtherapy |